Bibliographic information
GuidelineTherapeutics and COVID-19: living guideline, 13 January 2023.
Year of Publication2023
Issuing InstitutionWorld Health Organization
Recommendation
Maintained
For patients with non-severe COVID-19, we recommend not to use fluvoxamine, except in the context of a clinical trial
Recommended against
Strong
Notes and Remarks
- Several therapeutic op tions are recommended f or patients with non-se vere COVID-19 including nirmatrelvir-ritonavir, molnupiravir, and remdesivir.
- For choosing betw een the ther apeutic op tions, see S ection 6.1 and the decision support t ool, which display s benefits and harms o f the options.
Also Featured In
This recommendation also appears in the following guidelines:
Originally Developed
Guideline
Therapeutics and COVID-19: living guideline, 14 July 2022.
Year2022
InstitutionWHO
Guideline
Therapeutics and COVID-19: living guideline, 16 September 2022.
Year2022
InstitutionWorld Health Organization
Guideline
Therapeutics and COVID-19: living guideline, 10 November 2023.
Year2023
InstitutionWorld Health Organization
Guideline
Therapeutics and COVID-19: living guideline, August 2025
Year2025
InstitutionWorld Health Organization